"The process of developing and generating a new drug or treatment normally takes up to three years, and costs have nearly quadrupled in the past 15 years," said Prof. Marek Niezgodka, Director of ICM. "With Nostromo, we expect to increase the simulation speed which will bring us much closer to the era of "personalized medicine," when preventative approaches can be tailored to a specific condition."Nostromo currently ranks N 143 on the Top500.org list and N 9 on Green500.org. The system has already been installed by IBM Poland and Qumak SA, IBM's Business Partner.
ICM's New Blue Gene Supercomputer Supports The Largest Biomedical Research Initiative In Poland
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.